Combination therapy including antibiotics may be beneficial for multiple sclerosis

A preliminary study suggests that combining a medication currently used to treat multiple sclerosis with an antibiotic may slow the progress of the disease, according to an article posted online today that will appear in the February 2008 print issue of Archives of Neurology, one of the JAMA/Archives journals.

“Multiple sclerosis (MS) is an immune-mediated disorder that affects genetically susceptible individuals after exposure to certain, as yet unidentified environmental antigens,” or disease-causing agents, the authors write as background information in the article. The development of MS involves inflammation that destroys parts of the brain along with progressive degeneration of brain tissue.

The most common type is relapsing-remitting MS, in which patients experience attacks of symptoms such as muscle weakness and spasms followed by periods of symptom-free remission. Many patients with relapsing-remitting MS who take interferon, a medication that boosts the immune system and fights viruses, still experience relapses and may continue to develop new areas of damaged brain tissue (lesions) visible on magnetic resonance imaging (MRI).

Alireza Minagar, M.D., of Louisiana State University Health Sciences Center, Shreveport, and colleagues conducted a single-center trial involving 15 patients (average age 44.5) with relapsing-remitting MS who had been taking interferon for at least six months and were experiencing symptoms and developing new brain lesions. For four months, participants took 100 milligrams daily of the antibiotic doxycycline in addition to continuing interferon therapy. They underwent monthly neurological examinations, MRI to detect brain lesions and blood work to monitor safety.

After four months, the combination treatment resulted in fewer lesions visible on MRI—60 percent of the patients had more than a one-fourth reduction in the number of lesions from the beginning of the study. The patients also had reduced average scores on a scale designed to assess disability levels. Only one patient relapsed; adverse effects were mild and included only known effects of the two drugs individually rather than new effects associated with combining the medications.

Antibiotics in the tetracycline family, including doxycycline, may be effective against MS and other inflammatory diseases by inhibiting the action of enzymes that destroy certain nervous system cells, protecting the brain and increasing the effectiveness of the immune system, the authors note.

Source: JAMA and Archives Journals

Related stories:

Barrow scientists solve 200-year-old scientific debate involving visual illusions
Neuroscientists at Barrow Neurological Institute at St. Joseph's Hospital and Medical Center have discovered a direct link between eye motions and the perception of illusory motion that solves a 200-year-old debate.
Optical illusions: caused by eye or brain?
When viewing the famous optical illusion painting Enigma by Isia Leviant, many people claim to see motion within the colored circles moving against the black and white striped background. Although this optical illusion has been known for a long time, its physiological origins are still unknown.
Multiple sclerosis progression can be predicted with MRI
A new study published in Journal of Neuroimaging shows that MRI scans used on multiple sclerosis (MS) patients to determine if the disease has affected gray matter in the brain can identify those at-risk for progression of disability.
Vitamin B3 reduces Alzheimer's symptoms, lesions
An over-the-counter vitamin in high doses prevented memory loss in mice with Alzheimer's disease, and UC Irvine scientists now are conducting a clinical trial to determine its effect in humans.
Scientists adapt economics theory to trace brain's information flow
Scientists have used a technique originally developed for economic study to become the first to overcome a significant challenge in brain research: determining the flow of information from one part of the brain to another.
Risk and reward compete in brain
That familiar pull between the promise of victory and the dread of defeat – whether in money, love or sport – is rooted in the brain's architecture, according to a new imaging study.
Rare genetic disorder gives clues to autism, epilepsy, mental retardation
A rare genetic disorder called tuberous sclerosis complex (TSC) is yielding insight into a possible cause of some neurodevelopmental disorders: structural abnormalities in neurons, or brain cells. Researchers in the F.M. Kirby Neurobiology Center at Children's Hospital Boston, led by Mustafa Sahin, MD, PhD, and Xi He, PhD, also found that normal neuronal structure can potentially be restored.
The Schiavo case: Are mass media to be blamed?
In 1990, Theresa Schiavo, an American citizen, had a cardiac arrest that caused irreversible brain damage which led to a persistent vegetative state diagnosis. A few years later, this diagnosis became a source of conflict over the interruption of artificial nutrition. The "Schiavo Case" was widely discussed from a medical, ethical and social standpoint in the United States and elsewhere. In an article to be published in the September 23 issue of Neurology, the renowned journal of the American Academy of Neurology, and available online today, a team of bioethicists composed of Dr. Éric Racine of the Institut de recherches cliniques de Montréal (IRCM) and experts from Stanford University, in California, and the University of British Columbia examines the media coverage featuring this famous case.

News discussion:

Medicine & Health news